|Articles|June 1, 2003
- BioPharm International-06-02-2003
- Volume 2003 Supplement
- Issue 1
Inactivation of Viruses: An Introduction to the Series
Author(s)Gail Sofer
by Gail Sofer, BioReliance
Advertisement
Articles in this issue
over 22 years ago
Part 1: Skin, Bone, and Cellsover 22 years ago
BioPharm International's Virus Inactivation Series: A Prefaceover 22 years ago
Part 4: Culture Media, Biotechnology Products, and Vaccinesover 22 years ago
Part 6: Inactivation Methods Grouped by Virusover 22 years ago
Part 5: Disinfectionover 22 years ago
Part 2: Red Blood Cells and PlateletsNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Why AI-Native Cell Manufacturing Is the Future of Drug Discovery (Part 1)
2
GSK Advances Vaccine Delivery and Hepatitis B Treatment
3
What Are the Benefits of Single-Use in CGT Manufacturing?
4
New AI Oncology Alliance Highlights Industry Push for Scalable Genomics
5
